Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New modality showdowns
Genetic therapies compete in the same indications, as degraders come of age
BioCentury | Oct 29, 2024
Product Development
Market reaction to Intellia data suggests perfection remains bar for gene editing
Clinical Report: Celldex advances in a second urticaria type, Eledon’s mAb helps Type I diabetes patients become insulin-independent, and more
BioCentury | Jan 22, 2024
Product Development
Clinical roundup: new data from Gilead, Sagimet, Ionis, Novartis and BMS
Gilead falls on Trodelvy readout; plus Sagimet’s value-driving NASH data, and updates from Ionis, Novartis and BMS
BioCentury | Dec 20, 2023
Deals
Dec. 19 Quick Takes: Ionis, Otsuka in European deal for HAE therapy
Plus: Carmot spinout Kimia raises $55M series A round, CureVac tumbles on loss in patent case and more from Lassen, Atavistik, Crinetics, Merck and CSL
BioCentury | Jun 26, 2021
Product Development
Intellia delivers transformative potential with in vivo gene editing
Intellia’s CRISPR-Cas9 platform threatens to disrupt other new modality markets
BioCentury | Mar 29, 2021
Product Development
March 29 Quick Takes: Humanigen mAb meets COVID endpoint; plus Merck, Wave, Celldex, Ionis, Orphazyme and uniQure
Humanigen Inc. (NASDAQ:HGEN) shares rose 54% to $21.61 Monday after the company said top-line data showed lenzilumab improved survival without the need for mechanical ventilation in hospitalized
Items per page:
1 - 8 of 8